PSA over 4 ng/mL

The first thing a guideline says to do with a new PSA above 4.0 ng/mL is measure it again. AUA/SUO Statement 3: "For people with a newly elevated PSA, clinicians should repeat the PSA prior to a secondary biomarker, imaging, or biopsy." The reason is in the discussion: "it will return to a normal level in 25% to 40% upon retesting," and in one Stockholm study 17 percent of men with a PSA of 3 to 10 were under 3 on a second draw eight weeks later. The bodies differ on timing. NCI says a repeat "in 6 to 8 weeks"; the AUA says "a repeat PSA in a few months." The AUA panel strongly supports the Choosing Wisely position that empiric antibiotics should not be used for an elevated PSA in someone without symptoms.

What moves PSA without cancer. NCI: benign prostatic hyperplasia and prostatitis raise it, an infection or a recent biopsy can keep it up "for a month or two," and ejaculation raises it transiently, so NCI advises avoiding activities that raise PSA for 2 days before a test. The AUA adds urinary tract infection, catheterization, cystoscopy and urinary retention, and puts ejaculation at a modest increase of about 10 percent. On cycling the two disagree: NCI lists it as a transient raiser, the AUA says "Neither DRE nor bicycle riding appreciably alters the PSA." Finasteride and dutasteride lower PSA; the AUA discussion notes older studies suggested doubling the reading after at least 6 months on the drug, then cautions that only about a third of patients in one trial showed the expected 40 to 60 percent fall at one year.

What comes after a confirmed elevation. The AUA does not send a confirmed result straight to biopsy. A rectal exam may be used alongside PSA (Statement 8), validated risk calculators may combine PSA with age, family history, race, percent free PSA and PSA density (Statement 10), and a rising PSA on its own must not be the sole trigger for imaging or biopsy (Statement 9, Strong, Grade B). MRI before a first biopsy is a Conditional recommendation with Grade A evidence (Statement 13), with the caveat that a negative MRI still misses roughly 1 in 10 clinically significant cancers. Blood and urine markers such as percent free PSA are for the "mildly elevated" range of about 2.5 to 10 ng/mL, where a lower free fraction means a higher chance of cancer on biopsy (Statement 17). When risk is sufficiently low on all of that, the AUA says biopsy may be deferred (Statement 11).

What a biopsy finds. NCI, citing the PLCO trial: "only about 25% of men who have a biopsy due to an elevated PSA level are found to have prostate cancer." A negative biopsy does not end screening (Statement 20), and a later PSA threshold alone should not decide whether to repeat it (Statement 21). At the far end, the AUA allows omitting biopsy for a PSA over 50 with no sign of infection when the need for treatment is urgent (Statement 18).